Oxygenta Pharma Peer Comparison
BSE: 524636
₹57.78
₹-1.70
(-2.86%)
As on 28-Aug-2026IST
Market cap
₹214 Cr
Revenue (TTM)
₹135 Cr
P/E Ratio
--
P/B Ratio
-4.8
Div. Yield
0 %
Edit
| Oxygenta Pharma | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
214 | 32,104 | 29,892 | 29,103 | 26,871 |
Revenue (₹ Cr) |
135 | 3,564 | 1,936 | 9,205 | 1,462 |
Net Profit (₹ Cr) |
-13.58 | 414.00 | 288.22 | -371.81 | 387.35 |
Net Margin (%) |
-10.06 | 11.23 | 14.79 | -3.93 | 26.01 |
RoE (%) |
-- | 8.38 | 29.77 | -3.85 | 25.18 |
Price to Earnings |
-- | 78.49 | 103.71 | -- | 69.57 |
Price-To-Book |
-4.77 | 6.38 | 22.27 | 3.64 | 15.55 |
Income Statement (₹ Cr)
| Oxygenta Pharma | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Operating Revenue
|
112.98 | 3,373.00 | 1,753.96 | 8,869.08 | 1,006.88 |
|
Total Income
|
113.27 | 3,510.00 | 1,762.66 | 9,111.51 | 1,023.80 |
|
Total Expenditure
|
128.29 | 2,747.00 | 1,354.69 | 7,976.59 | 774.80 |
|
EBITDA
|
-15.31 | 626.00 | 399.26 | 892.49 | 232.07 |
|
Depreciation
|
2.32 | 227.00 | 45.26 | 831.24 | 26.62 |
|
EBIT
|
-17.63 | 399.00 | 354.00 | 61.25 | 205.45 |
|
Interest
|
4.83 | 213.00 | 42.17 | 340.80 | 6.22 |
|
Other Income
|
0.29 | 137.00 | 8.70 | 242.43 | 16.93 |
|
Exceptional Items
|
-- | -85.00 | -- | -196.14 | -- |
|
Profit before Tax
|
-22.18 | 238.00 | 320.53 | -176.06 | 216.16 |
|
Provision for Tax
|
-4.61 | 39.00 | 73.80 | 149.88 | 55.75 |
|
Profit after Tax
|
-17.57 | 199.00 | 246.74 | -325.94 | 160.42 |
Liabilities (₹ Cr)
| Oxygenta Pharma | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-42.69 | 4,940.00 | 1,288.82 | 8,162.62 | 1,309.63 |
|
Minority Interest
|
-- | 341.00 | 0.00 | -- | 10.45 |
|
Non-Current Liabilities
|
58.86 | 1,235.00 | 189.02 | 4,529.41 | 26.93 |
|
Current Liabilities
|
86.10 | 1,622.00 | 835.87 | 4,874.74 | 202.25 |
|
Total Liabilities
|
119.68 | 8,578.00 | 2,326.71 | 17,723.32 | 1,549.26 |
Assets (₹ Cr)
| Oxygenta Pharma | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
50.84 | 5,441.00 | 631.90 | 10,258.66 | 757.63 |
|
Current Assets
|
51.43 | 2,606.00 | 1,681.81 | 7,308.11 | 791.64 |
|
Total Assets
|
119.68 | 8,578.00 | 2,326.71 | 17,723.32 | 1,549.26 |
|
Total Debt*
|
109.57 | 2,125.00 | 259.37 | 5,495.48 | 8.18 |
|
Net Current Assets
|
-34.67 | 984.00 | 845.94 | 2,433.37 | 589.39 |
|
Contingent Liabilities
|
0.17 | 768.26 | 19.09 | 95.72 | 15.38 |
Cashflow (₹ Cr)
| Oxygenta Pharma | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-27.75 | 390.00 | 205.05 | 1,652.60 | 118.34 |
|
Cash Flow from Investing Activities
|
-14.39 | -241.00 | -409.72 | -826.03 | -223.94 |
|
Cash from Financing Activities
|
42.56 | -54.00 | 283.07 | -38.98 | 261.12 |
|
Net Cash Inflow / Outflow
|
0.42 | 95.00 | 78.39 | 787.59 | 155.52 |
Ratios
Profitability Ratios
| Oxygenta Pharma | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-33.53 | 6.79 | 29.22 | 1.24 | 20.14 |
|
ROE (%)
|
0.00 | 4.29 | 27.84 | -4.04 | 16.19 |
|
ROA (%)
|
-20.42 | 2.53 | 13.11 | -1.98 | 12.13 |
|
EBIT Margin (%)
|
-13.30 | 22.62 | 23.26 | 12.80 | 24.73 |
|
Net Margin (%)
|
-15.51 | 5.67 | 14.00 | -3.58 | 15.67 |
|
Cash Profit Margin (%)
|
-13.50 | 10.98 | 7.71 | 4.80 | 18.58 |
Growth Ratios
| Oxygenta Pharma | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
3.37 | 11.99 | 36.57 | -3.08 | 40.34 |
|
EBIT Growth (%)
|
-76.64 | 67.69 | 52.29 | -28.15 | 83.12 |
|
Net Profit Growth (%)
|
-70.63 | 449.12 | 83.64 | -457.66 | 229.35 |
|
EPS Growth (%)
|
-70.62 | 553.20 | 71.44 | -456.91 | 67.16 |
|
Book Value Growth (%)
|
-66.48 | 13.47 | 144.31 | 0.33 | 94.96 |
Valuation Ratios
| Oxygenta Pharma | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Price / Earnings
|
0.00 | 89.54 | 51.69 | 0.00 | 62.97 |
|
Price / Book Value
|
-4.19 | 3.87 | 10.14 | 2.24 | 15.26 |
|
Dividend Yield (%)
|
0.00 | 0.00 | 0.19 | 0.00 | 0.06 |
|
EV/EBITDA
|
-19.06 | 27.45 | 31.05 | 19.72 | 79.31 |
|
Market Cap (₹ Cr)
|
178.93 | 19,071.62 | 12,753.19 | 18,108.89 | 19,988.69 |
Solvency Ratios
| Oxygenta Pharma | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-2.57 | 0.43 | 0.21 | 0.68 | 0.01 |
|
Short term debt to equity ratio
|
-0.74 | 0.09 | 0.05 | 0.09 | 0.01 |
|
Current Ratio
|
0.60 | 1.61 | 2.01 | 1.50 | 3.91 |
|
Quick Ratio
|
0.26 | 1.06 | 1.14 | 0.87 | 3.02 |
|
Interest Coverage
|
-3.59 | 2.12 | 8.60 | 0.48 | 35.76 |
Operating Efficiency Ratios
| Oxygenta Pharma | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
8.88 | 17.43 | 29.00 | 24.33 | 28.85 |
|
Asset Turnover
|
1.31 | 0.49 | 2.01 | 0.64 | 0.76 |
|
Receivable days
|
24.43 | 58.75 | 40.13 | 78.20 | 90.06 |
|
Inventory Days
|
80.66 | 75.82 | 60.29 | 93.30 | 61.02 |
|
Payable days
|
140.38 | 186.21 | 232.47 | 226.14 | 96.06 |
|
Cash Conversion Cycle
|
-35.29 | -51.64 | -132.04 | -54.64 | 55.02 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
